F2G Ltd., Manchester, United Kingdom.
UCL Institute of Ophthalmology, London, United Kingdom.
PLoS One. 2023 Aug 2;18(8):e0289441. doi: 10.1371/journal.pone.0289441. eCollection 2023.
Olorofim is a new antifungal in clinical development which has a novel mechanism of action against dihydroorotate dehydrogenase (DHODH). DHODH form a ubiquitous family of enzymes in the de novo pyrimidine biosynthetic pathway and are split into class 1A, class 1B and class 2. Olorofim specifically targets the fungal class 2 DHODH present in a range of pathogenic moulds. The nature and number of DHODH present in many fungal species have not been addressed for large clades of this kingdom. Mucorales species do not respond to olorofim; previous work suggests they have only class 1A DHODH and so lack the class 2 target that olorofim inhibits. The dematiaceous moulds have mixed susceptibility to olorofim, yet previous analyses imply that they have class 2 DHODH. As this is at odds with their intermediate susceptibility to olorofim, we hypothesised that these pathogens may maintain a second class of DHODH, facilitating pyrimidine biosynthesis in the presence of olorofim. The aim of this study was to investigate the DHODH repertoire of clinically relevant species of Mucorales and dematiaceous moulds to further characterise these pathogens and understand variations in olorofim susceptibility. Using bioinformatic analysis, S. cerevisiae complementation and biochemical assays of recombinant protein, we provide the first evidence that two representative members of the Mucorales have only class 1A DHODH, substantiating a lack of olorofim susceptibility. In contrast, bioinformatic analyses initially suggested that seven dematiaceous species appeared to harbour both class 1A-like and class 2-like DHODH genes. However, further experimental investigation of the putative class 1A-like genes through yeast complementation and biochemical assays characterised them as dihydrouracil oxidases rather than DHODHs. These data demonstrate variation in dematiaceous mould olorofim susceptibility is not due to a secondary DHODH and builds on the growing picture of fungal dihydrouracil oxidases as an example of horizontal gene transfer.
奥洛福米是一种新的抗真菌药物,正在临床开发中,它具有一种针对二氢乳清酸脱氢酶 (DHODH) 的新型作用机制。DHODH 是从头嘧啶生物合成途径中普遍存在的酶家族,分为 1A 类、1B 类和 2 类。奥洛福米专门针对存在于多种致病性霉菌中的真菌 2 类 DHODH。尚未针对这个王国的许多真菌物种的大分支解决 DHODH 的性质和数量。毛霉科物种对奥洛福米没有反应;先前的工作表明,它们只有 1A 类 DHODH,因此缺乏奥洛福米抑制的 2 类靶标。暗色真菌对奥洛福米具有混合敏感性,但先前的分析表明它们具有 2 类 DHODH。由于这与它们对奥洛福米的中度敏感性不一致,我们假设这些病原体可能维持第二类 DHODH,在奥洛福米存在的情况下促进嘧啶生物合成。本研究旨在研究临床上相关的毛霉科和暗色真菌的 DHODH 库,以进一步表征这些病原体并了解奥洛福米敏感性的变化。通过生物信息学分析、酿酒酵母互补和重组蛋白的生化分析,我们首次提供证据表明,毛霉科的两个代表性成员仅具有 1A 类 DHODH,证实了缺乏奥洛福米敏感性。相比之下,生物信息学分析最初表明,七种暗色真菌似乎都具有 1A 类样和 2 类样 DHODH 基因。然而,通过酵母互补和生化分析对假定的 1A 类样基因的进一步实验研究将其表征为二氢尿嘧啶氧化酶而不是 DHODH。这些数据表明,暗色真菌对奥洛福米敏感性的差异不是由于第二类 DHODH 引起的,并且为真菌二氢尿嘧啶氧化酶作为水平基因转移的一个例子提供了更多的信息。